Skip to main content

Table 4 Response criteria for cellular immunotherapy in both leukemia and lymphoma [[26],[27]]

From: Cellular immunotherapy for refractory hematological malignancies

 

AML/ALL

Lymphoma

Complete Remission (CR)

• No leukemic blasts in PB

Nodal

• No extramedullary leukemia

• If PET positive prior to treatment then any mass provided PET negative. If PET negative or variably positive then nodal regression to normal size on CT

• BM cellularity > 20% without Auer rods and <5% blasts

• ANC > 1.0 × 109/L

Spleen/Liver

• Platelet count > 100x109/L.

• Not palpable, resolution of nodules

Bone Marrow

• Morphological clearance or if morphology equivocal then IHC normalization

Partial Remission (PR)

• All criteria for CR except bone marrow may have 5-20% blasts

Nodal

• ≥ 50% decrease in the SPD of up to 6

• largest masses

Spleen/Liver

• ≥ 50% decrease in SPD of nodules if multiple nodules, ≥ 50% in size of the transverse diameter of a single nodule if solitary mass

Bone Marrow

• No new bone marrow involvement

Transient Response (TR)

• Loss of PB blasts

N/A

• >50% reduction in BM blasts

Stable Disease (SD)

N/A

• If PET positive pretreatment, then PET positive post treatment at previous sites. If PET negative pretreatment then no CT change in size of previous lesions.